- Title: Purdue Pharma offers 10 to 12 billion dollars to settle opioid claims - NBC
- Date: 27th August 2019
- Summary: INDIANA COUNTY, PENNSYLVANIA, UNITED STATES (FILE) (REUTERS) VARIOUS OF CEMETERY
- Embargoed: 10th September 2019 21:39
- Keywords: OxyContin Purdue Pharma settlement opioid Johnson & Johnson
- Location: MIDDLETOWN, OHIO; INDIANA COUNTY, PENNSYLVANIA, PROVO, UTAH AND UNKNOWN LOCATION, UNITED STATES
- City: MIDDLETOWN, OHIO; INDIANA COUNTY, PENNSYLVANIA, PROVO, UTAH AND UNKNOWN LOCATION, UNITED STATES
- Country: USA
- Topics: Crime/Law/Justice,Judicial Process/Court Cases/Court Decisions
- Reuters ID: LVA004ATZW2MF
- Aspect Ratio: 16:9
- Story Text: OxyContin maker Purdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10 billion to $12 billion, NBC News reported on Tuesday (August 27) citing two people familiar with the mediation.
Purdue is among several drugmakers and distributors that are facing lawsuits, seeking to hold them responsible for fueling the U.S. opioid addiction crisis, which has claimed thousands of lives.
Purdue said it was actively working with state attorneys general and other plaintiffs to reach a resolution, without specifying a settlement amount.
NBC's report comes a day after an Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for deceptively marketing addictive painkillers.
Purdue in March reached a settlement for $270 million to resolve a similar lawsuit by the state of Oklahoma.
The potential deal reported by NBC was part of a confidential meeting held in Cleveland, Ohio, last week between state attorneys general, plaintiffs' attorneys and Purdue's lawyers.
The lawsuits have accused the Stamford, Connecticut-based company of aggressively marketing prescription 3 while misleading prescribers and consumers about risks from their prolonged use.
(Production: Arlene Eiras) - Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2019. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None